First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial.
Karl Oliver KaganF SrokaJ SonekH AbeleK LüthgensM SchmidP WagnerS BruckerD WallwienerM HoopmannPublished in: Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2018)
Our study has shown that first-trimester risk assessment for trisomy 21 that includes a detailed ultrasound examination as well as NT measurement and is followed by cfDNA testing is associated with a significant reduction in the false-positive rate compared with FTCS. This approach obviates the need for maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A in screening for fetal aneuploidy. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
Keyphrases
- risk assessment
- magnetic resonance imaging
- human health
- endothelial cells
- heavy metals
- pregnancy outcomes
- contrast enhanced ultrasound
- preterm birth
- ultrasound guided
- induced pluripotent stem cells
- pregnant women
- randomized controlled trial
- amino acid
- protein protein
- birth weight
- binding protein
- systematic review
- physical activity
- body mass index